First-line treatment of ovarian cancer: questions and controversies to address by Jonathan A. Ledermann

Get full text

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer by Jonathan A. Ledermann, Eric Pujade-Lauraine

Get full text

Treatment options in recurrent ovarian cancer: latest evidence and clinical potential by Daniela Luvero, Andrea Milani, Jonathan A. Ledermann

Get full text

Self-supervised deep learning for highly efficient spatial immunophenotypingResearch in context by Hanyun Zhang, Khalid AbdulJabbar, Tami Grunewald, Ayse U. Akarca, Yeman Hagos, Faranak Sobhani, Catherine S.Y. Lecat, Dominic Patel, Lydia Lee, Manuel Rodriguez-Justo, Kwee Yong, Jonathan A. Ledermann, John Le Quesne, E. Shelley Hwang, Teresa Marafioti, Yinyin Yuan

Get full text

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease... by Ana Oaknin, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Susana Banerjee, Jesus García‐Donas, Elizabeth M. Swisher, Terri Cameron, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman

Get full text